Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
开发一种治疗致命性神经内分泌前列腺癌的新型组合疗法
基本信息
- 批准号:10518805
- 负责人:
- 金额:$ 38.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:ArchitectureBCL2 geneBiological AssayBiological MarkersBiological ModelsBritish ColumbiaCastrationCell DeathCell LineCellsCellular AssayCessation of lifeCharacteristicsClinicClinicalClinical TrialsCollaborationsDataDevelopmentDrug CombinationsEventFutureGenetically Engineered MouseHeterogeneityHumanImmunodeficient MouseIn VitroIronLipid PeroxidationMalignant NeoplasmsMalignant neoplasm of prostateMetastatic Prostate CancerMolecularMolecular GeneticsNeoplasm MetastasisNeuroendocrine Prostate CancerNeuroendocrine TherapyNeuroendocrine TumorsPathway interactionsPatientsPreclinical TestingProstate AdenocarcinomaProstaticRB1 geneResearchResistanceRetinoblastomaRetinoblastoma ProteinSafetySpecimenTestingTherapeuticTissuesTranslationsTreatment EfficacyUniversitiesValidationVisceral metastasisWorkXenograft ModelXenograft procedurebasecombinatorialcytotoxicitydesignhormone therapyimplantationin vivoin vivo evaluationinhibitorinsightinterdisciplinary approachloss of functionlung small cell carcinomaneuroendocrine differentiationnovelnovel drug combinationpalliativepatient derived xenograft modelpre-clinicalpreclinical studyprostate cancer cellprostate cancer modelscreeningtargeted treatmenttumor
项目摘要
Project Summary/Abstract
Neuroendocrine prostate cancer (NEPC) is a highly aggressive subtype of prostate cancer that can arise de
novo, but more commonly develops after hormone therapies for advanced prostate adenocarcinoma (PADC). It
accounts for up to 25% of deaths related to prostate cancer. Current treatment options for NEPC are only
palliative, and most patients die within several months. Therefore, there is a pressing unmet need to develop
effective targeted therapies for patients with NEPC.
Among molecular events associated with NEPC, loss of retinoblastoma (RB) protein occurs nearly
universally and drives prostate cancer castration resistance, metastasis, lineage plasticity, and lethality, which
suggests that RB1 loss is a pivotal event in the development of NEPC and may be exploited to identify and target
therapeutic vulnerabilities in NEPC. In our recent research into the molecular and genetic events underlying
ferroptosis, a form of regulated cell death driven by iron-dependent lipid peroxidation, we discovered that RB1
disruptions significantly sensitize prostate cancer cells to ferroptosis, at least in part, through a RB/E2F/ACSL4
axis, and that ferroptosis inducers preferentially kill RB1-null NEPC cells rather than RB1-intact PADC cells,
implying the therapeutic potential of ferroptosis inducers in the treatment of NEPC. Given that NEPC is
notoriously hard to treat and monotherapy often benefits only a small portion of patients, as is the cases with
other poorly differentiated neuroendocrine tumors such as small-cell carcinoma of the lung, we propose to
develop an effective combinatorial therapy for NEPC based on targeting ferroptosis. Our exciting unpublished
preliminary data has shown that the combination of the ferroptosis inducer with the BCL2 inhibitor strongly
induces synergistic cytotoxicity in NEPC cells both in vitro and in cell line-derived xenograft (CDX) models of
NEPC. Based on these compelling preliminary findings, we hypothesize that ferroptosis inducers and BCL2
inhibitors synergistically promote cell death pathways in NEPC cells, and that co-targeting ferroptosis and BCL2
represents a promising combinatorial approach to treating lethal NEPC. Through a multidisciplinary approach
combining unique prostate cancer model systems, in vivo preclinical studies, and well-established molecular and
cellular assays, we aim to determine whether co-targeting ferroptosis and BCL2 represents a promising
combinatorial approach to treating lethal NEPC. In Aim 1, we will determine the therapeutic efficacy of ferroptosis
induction combined with BCL2 inhibition in patient-derived xenograft models of NEPC. In Aim 2, we will determine
the therapeutic efficacy of ferroptosis induction combined with BCL2 inhibition in genetically engineered mouse
models of NEPC. In Aim 3, we will elucidate the molecular mechanisms underlying the anti-tumor activity of
ferroptosis induction combined with BCL2 inhibition in NEPC.
项目总结/文摘
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MING CHEN其他文献
MING CHEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MING CHEN', 18)}}的其他基金
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology
在小鼠中进行大量染色体缺失以推进精准肿瘤学
- 批准号:
10445187 - 财政年份:2022
- 资助金额:
$ 38.54万 - 项目类别:
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer
开发一种针对致命性神经内分泌前列腺癌的新型组合疗法
- 批准号:
10664011 - 财政年份:2022
- 资助金额:
$ 38.54万 - 项目类别:
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology
在小鼠中进行大量染色体缺失以推进精准肿瘤学
- 批准号:
10579292 - 财政年份:2022
- 资助金额:
$ 38.54万 - 项目类别:
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer
靶向致命性 RB1 缺陷型前列腺癌中的铁死亡
- 批准号:
10413399 - 财政年份:2022
- 资助金额:
$ 38.54万 - 项目类别:
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer
靶向致命性 RB1 缺陷型前列腺癌中的铁死亡
- 批准号:
10588173 - 财政年份:2022
- 资助金额:
$ 38.54万 - 项目类别:
CYTOKINE-MEDIATED PATHOPHYSIOLOGY IN FANCONI ANEMIA
范可尼贫血中细胞因子介导的病理生理学
- 批准号:
6526631 - 财政年份:2002
- 资助金额:
$ 38.54万 - 项目类别:
CYTOKINE-MEDIATED PATHOPHYSIOLOGY IN FANCONI ANEMIA
范可尼贫血中细胞因子介导的病理生理学
- 批准号:
6402758 - 财政年份:2001
- 资助金额:
$ 38.54万 - 项目类别:
CYTOKINE-MEDIATED PATHOPHYSIOLOGY IN FANCONI ANEMIA
范可尼贫血中细胞因子介导的病理生理学
- 批准号:
6211564 - 财政年份:2000
- 资助金额:
$ 38.54万 - 项目类别:
相似海外基金
The Development of Novel Inhibitors of BCL2 Gene Expression as Anticancer Therape
开发新型 BCL2 基因表达抑制剂作为抗癌疗法
- 批准号:
8642980 - 财政年份:2014
- 资助金额:
$ 38.54万 - 项目类别:
BCL2 GENE FAMILY, APOPTOSIS RESISTANCE AND BREAST CANCE
BCL2 基因家族、细胞凋亡抗性和乳腺癌
- 批准号:
2795904 - 财政年份:1996
- 资助金额:
$ 38.54万 - 项目类别: